Compare LYFT Inc (LYFT) vs TG Therapeutics Inc (TGTX) Price & Performance

Lyft trades at $16.42, down 4.87% today, with a bullish technical outlook from moving averages but bearish oscillators. The company reported Q2 2026 revenue growth of 16.1% to a record $5.5 billion in gross bookings, though EPS missed estimates. Strong cash flow generation and expanding global rider base support fundamentals, while valuation ratios like P/E of 2.55 appear attractive relative to historical norms.

Lyft's outlook is mixed: robust revenue growth and cash flow provide upside potential, but earnings misses and competitive pressures from Uber pose risks. The stock offers value with a consensus price target of $19.17, representing 17% upside, though investors face headwinds from rising expenses and market share battles in the ride-hailing sector.

TG Therapeutics (TGTX) trades at $49.66, up 1.02% on the day, with a bearish technical signal and recent earnings misses despite strong revenue growth. The company reported Q2 2026 revenue of $240 million and raised full-year BRIUMVI guidance to $950 million, but net income was impacted by manufacturing investments. Valuation ratios show a high P/E of 18.22 and EV/EBITDA of 56.26, while profitability metrics like ROE of 100.28% remain robust.

Outlook is mixed: strong product demand and raised revenue targets support growth, but earnings volatility and a bearish technical trend pose risks. Analyst consensus is bullish with an $63.75 price target, though legal investigations and competitive pressures require monitoring for stock investors.